Wormwood in Chronic Progressive Disorders With Reduced Appetite

NCT01126931 | Unknown

• 1 other identifier: Appetite and Weight Loss
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Wormwood is approved herbal medicine for the treatment of reduced appetite in Germany (Registration No.: 1339.99.99). Reduced appetite is observed in many chronic health disorders such as old age, immune disorders and cancer. Trial aims at observing beneficial effects of wormwood supplementation in various chronic disorders associated with reduced appetite

Conditions

Cancer

Keywords

Crohn disease; Involuntary weight loss in cancer; IgA nephropathy; Depression with reduced appetite

Outcome Measures

Primary Outcomes (1)

• Improvement in appetite

  6-12 months

Secondary Outcomes (1)

• Improvement in quality of life

  12-24 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient with reduced appetite and reduced quality of life as a result of chronic progressive disorders such as cancer, autoimmune diseases (Crohn, IgA-Nephropathy), old age and depression

You may qualify if:

• Appetite and weight loss
• Chronic progressive disease

You may not qualify if:

• Life expectancy less than 3 months

Sponsors & Collaborators

• University Hospital Freiburg: lead

Study Sites (1)

University of Freiburg, Medical Faculty

Freiburg im Breisgau, Baden, 79110, Germany

RECRUITING

Related Publications (3)

• Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine. 2007 Feb;14(2-3):87-95. doi: 10.1016/j.phymed.2007.01.001. Epub 2007 Jan 19.

  PMID: 17240130 BACKGROUND

• Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - A controlled clinical trial. Phytomedicine. 2010 Apr;17(5):305-9. doi: 10.1016/j.phymed.2009.10.013. Epub 2009 Dec 3.

  PMID: 19962291 BACKGROUND

• Krebs S, Omer B, Omer TN, Fliser D. Wormwood (Artemisia absinthium) for poorly responsive early-stage IgA nephropathy: a pilot uncontrolled trial. Am J Kidney Dis. 2010 Dec;56(6):1095-9. doi: 10.1053/j.ajkd.2010.06.025. Epub 2010 Sep 16.

  PMID: 20843592 DERIVED

MeSH Terms

Conditions

Neoplasms; Crohn Disease; Glomerulonephritis, IGA

Condition Hierarchy (Ancestors)

Inflammatory Bowel Diseases; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases; Glomerulonephritis; Nephritis; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Simone S Krebs, MD, PhD

  University of Freiburg, Nuclear Medicine, Germany

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Simone S Krebs, MD, Ph.D

CONTACT

(+49) -761-27-3913; simone.krebs@uniklinik-freiburg.de

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: May 17, 2010
• First Posted: May 20, 2010
• Study Start: February 1, 2006
• Primary Completion: August 1, 2012
• Study Completion: December 1, 2012
• Last Updated: May 20, 2010

Record last verified: 2008-02

Locations

DE (1)